5-甲基吡嗪-2-甲醛 | 50866-30-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-甲基吡嗪-2-甲醛
• 中文别名: 5-甲基-2-醛基吡嗪
• 英文名称: 5-methylpyrazine-2-carbaldehyde
• CAS: 50866-30-3
• 化学式: C₆H₆N₂O
• mdl: MFCD10697792
• 分子量: 122.126
• InChiKey: JUPFEWGPEBACJP-UHFFFAOYSA-N

物化性质

• 熔点：
  10-15℃
• 沸点：
  273℃
• 密度：
  1.176
• 闪点：
  79℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  温度：2-8°C，保持在惰性气体氛围中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Methylpyrazine-2-carbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methylpyrazine-2-carbaldehyde
CAS number: 50866-30-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6N2O
Molecular weight: 122.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基吡嗪-2-甲醛 在 (2S)-2-[二苯基[(三甲基硅酯)氧基]甲基]-吡咯烷 、 甲醇 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 25.25h， 生成 tert-butyl N-hydroxy-N-[(1S)-3-hydroxy-1-(5-methylpyrazin-2-yl)propyl]carbamate
  参考文献：
  名称：

  [EN] ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
  [FR] ISOXAZOLIDINES EN TANT QU'INHIBITEURS DE RIPK1 ET LEUR UTILISATION

  摘要：

  本发明涉及式I的异噁唑啉及其作为受体相互作用蛋白激酶1抑制剂的用途，例如用于治疗由RIP激酶（1）介导的疾病和紊乱，如类风湿性关节炎（RA）、牛皮癣、炎症性肠病（IBD）、克罗恩病或溃疡性结肠炎。

  公开号：

  WO2021245070A1
• 作为产物：
  描述：

  5-甲基吡嗪-2-羧酸甲酯 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.0h， 以78%的产率得到5-甲基吡嗪-2-甲醛
  参考文献：
  名称：

  设计和合成用于HDAC8抑制的基于二嗪的panobinostat类似物。

  摘要：

  在计算分析的指导下，本文报道了四种新型的基于二嗪的组蛋白脱乙酰基酶抑制剂（HDACis）的设计，合成和评估。感兴趣的靶标（TOI）是panobinostat的类似物，panobinostat是报道的最有效且用途最广泛的HDACi之一。通过简单地用二嗪衍生物替换panobinostat的苯基核心，对HDAC2和HDAC8的对接研究表明，四种类似物的抑制活性与panobinostat相当。多步合成提供了可视化的目标TOI1，TOI2，TOI3-rev和TOI4，其生物学评估证实了HDAC8抑制的强度，TOI4在不同浓度下显示出最大的功效。

  DOI：

  10.3762/bjoc.16.59

文献信息

• [EN] TRIAZOLE AGONISTS OF THE APJ RECEPTOR<br/>[FR] TRIAZOLES AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2016187308A1

  公开（公告）日：2016-11-24

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一种的立体异构体，或它们的混合物是APJ受体的激动剂，并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构，其中变量的定义在此提供。
• [EN] TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS PHÉNYLE TRIAZOLE EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018093579A1

  公开（公告）日：2018-05-24

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一个的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构：(I)，(II)，其中变量的定义在此提供。
• [EN] TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR<br/>[FR] COMPOSÉS DE TRIAZOLE FURANE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018097944A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.

  式(I)和式(II)的化合物，其药用盐，任何上述化合物的立体异构体，或它们的混合物是APJ受体的激动剂，并且在治疗心血管和其他疾病方面有用。式(I)和式(II)的化合物具有以下结构：(I); (II)。中间体(V)也被要求。
• Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds
  申请人：Pfizer Inc.

  公开号：US20140228356A1

  公开（公告）日：2014-08-14

  The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R 1 and R 2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明涉及所披露的化合物、互变异构体和该化合物的药用可接受盐，其中该化合物具有如下式的结构， 变量R1和R2如规范中所定义。还披露了相应的药用组合物、治疗方法、合成方法和中间体。
• Discovery of novel indolin-2-one compounds as potent inhibitors of HsClpP for cancer treatment
  作者：Rao Song、Yang Yang、Jiasheng Huang、Wenliang Qiao、Baozhu Luo、Yuan Ju、Tao Yang、Youfu Luo

  DOI：10.1016/j.bioorg.2021.104820

  日期：2021.5

  Through the preliminary biological assay in vitro, including MTT assay and proteolytic activity assay, compound I was identified as the most potent inhibitor. Treatment with compound I impaired the migration of Hela cells. In addition, compound I disrupted the mitochondrial function, and reduced the level of the SDHB and induced the production of the ATF4. In general, compound I is a promising probe of

  人酪蛋白水解蛋白酶蛋白水解亚基 (HsClpP) 是一种高度保守的丝氨酸蛋白酶，通过去除受损和/或错误折叠的蛋白质在细胞稳态中发挥重要作用。最近，由于其在癌症增殖和转移中的关键作用，HsClpP 被认为是癌症治疗的有希望的靶点。在本文中，通过对 2086 种生物活性化学物质库的随机筛选，一种新型化合物I，3-(3,5-dibromo-4-hydroxybenzylidene) -5-iodoindolin-2-one，被鉴定为一种有效的抑制剂HsClpP。在此，合成了一系列化合物I衍生物，并评估了它们对多种癌细胞的抗癌活性。通过初步的体外生物学分析，包括MTT测定和蛋白水解活性测定，化合物I被鉴定为最有效的抑制剂。用化合物I处理会损害 Hela 细胞的迁移。此外，化合物I破坏了线粒体功能，降低了 SDHB 的水平并诱导了 ATF4 的产生。总的来说，化合物I是一种很有前景的 HsClpP